



MYSIMBA[®]: COMMERCIALIZATION AND DISTRIBUTORSHIP ARRANGEMENT WITH OREXIGEN THERAPEUTICS IRELAND LTD.

The wholly owned subsidiary of Orexigen Therapeutics, Inc. (OREX), and CHEPLAPHARM Arzneimittel GmbH have executed a distributorship agreement covering Germany, France and Austria for Mysimba[®] (naltrexone HCl / bupropion HCl prolonged release).

Under the terms of the agreement, CHEPLAPHARM will be responsible for all commercialization activity and expenses. Orexigen will supply Mysimba[®] to CHEPLAPHARM for a negotiated transfer price.

"CHEPLAPHARM's strong capabilities in weight management therapy and established relationships in the market make them an ideal partner to bring Mysimba[®] to patients in Germany, France and Austria," said Dr. Thomas Canell, EVP, Chief Operating Officer and President of Global Commercial Products of Orexigen. "With this agreement, we now have partnerships covering 48 countries worldwide. In Europe, Mysimba[®] has now launched in 16 countries, and we expect to launch in up to eight more countries by year end."

"We are excited about our partnership with Orexigen and are dedicated to using our experience to help bring Mysimba[®] to patients struggling with their weight and obesity in Germany, France and Austria," said Sebastian Braun, CHEPLAPHARM's Chief Executive Officer.

Obesity and related comorbidities are a significant health problem across Europe, including the combined population of 150 million people in Germany, France and Austria. The percentage of the adult population struggling with obesity in these countries is: Germany (20%), France (18%) and Austria (21%), which represents a significant number of individuals in these large markets. On average, more than 50% of the adult population in these countries are overweight (Source: Kompetenzzentrum Adipositas; IGES Institut; Weißbuch Adipositas, DAG, World Bank).

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of weight loss and obesity. The company's mission is to help improve the health and lives of patients struggling to lose weight. Orexigen's first product, Contrave[®] (naltrexone HCl and bupropion HCl extended release), was approved in the U.S. in September 2014. In the European Union, the medicine has been approved under the brand name Mysimba[™] (naltrexone HCl/ bupropion HCl prolonged release).

Millions around the globe continue to face challenges of weight loss. Orexigen is undertaking a range of development and commercialization activities, both on its own and with strategic partners, to bring Contrave[®] / Mysimba[™] to patients around the world.

As a patient-centric company, Orexigen continues to focus not only on innovating medicine for the treatment of obesity, but to also offer unique resources and healthcare delivery options to improve the patient experience.

Further information about Orexigen can be found at www.orexigen.com.

Orexigen Contact:

Jason Keyes

Chief Financial Officer

Orexigen Therapeutics, Inc.

+1-858-875-8600

jkeyes@orexigen.com

About CHEPLAPHARM

CHEPLAPHARM Arzneimittel GmbH was founded in 1998, with its company headquarters situated in Greifswald since the end of 2014. Its subsidiaries are based in Hamburg and Englewood in New Jersey, USA (15 miles from New York).

With a team of experienced experts, CHEPLAPHARM 's aim is to offer high-quality medications, dietary supplements, and cosmetics on the market. These products are manufactured under state-of-the-art conditions and strict quality control. CHEPLAPHARM sees itself as a provider of specialty pharma. The focus lies on active ingredient markets and clinical pictures that are too small for pharma corporate groups and generic producers. It is thus possible for CHEPLAPHARM to offer customers highly individual products. In many pharmaceutical forms and active ingredient markets, CHEPLAPHARM has a unique position.

CHEPLAPHARM holds more than 300 authorizations in more than 100 countries worldwide and has extensive experience in collaborating with our global distribution and marketing partners.

Currently, CHEPLAPHARM employs 180 highly qualified staff members and, together with its subsidiaries, generates an annual turnover of 200 million euros.

Press office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | [presse\(at\)cheplapharm.com](mailto:presse(at)cheplapharm.com)